Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on March 6, 2025
Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook
GlobeNewswire
·
March 6, 2025
First-in-class oral selective SMARCA2 (BRM) inhibitor FHD-909 (LY4050784) continues enrollment in Phase 1 trial for SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population FHD-909 preclinical combination …
Jushi Holdings Inc. Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
·
March 6, 2025
Full Year 2024 Net Loss of $48.8 Million Compared to Net Loss of $65.1 Million in 2023 Full Year 2024 Adjusted EBITDA of $46.2 Million Compared to $40.8 Million in 2023 Increased Quarterly and Annual Operational Cash Flow Compared to Prior Periods to $7.2 …
NextCure Provides Business Update and Reports Full Year 2024 Financial Results
GlobeNewswire
·
March 6, 2025
Completed cohort 1 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers in February 2025 and plan to initiate backfill cohorts in the second half of 2025 Cash of approximately $68.6 million expected to fund operations into the second half of 2026 …
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences
GlobeNewswire
·
March 6, 2025
GARDEN CITY, N.Y., March 06, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives …
Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro™ in Pilot Launch Sets the Stage for Full Commercial Roll-Out
GlobeNewswire
·
March 6, 2025
– Overall BioEnvelope sales up 18%, with same-center sales increasing 65% following EluPro commercialization – SILVER SPRING, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting …
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire
·
March 6, 2025
Successful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Program for Hepatitis C Virus (HCV) Patient Enrollment in Global Phase 3 HCV Program Expected to Start in April 2025 Conference Call at 4:30 pm ET Today BOSTON, March 06, 2025 (GLOBE …
Profound Medical Announces Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
·
March 6, 2025
TORONTO, March 06, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased …
aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
GlobeNewswire
·
March 6, 2025
SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase …
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
·
March 6, 2025
Clinical data on track for Q2 2025 in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC Expansion of investigator sponsored “window of opportunity” trial into newly diagnosed glioblastoma patients with EGFR aberrations expected in Q1 …
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
·
March 6, 2025
– Presented positive updated data from ASPEN-06 Phase 2 trial demonstrating evorpacept generates strong response and durable clinical benefit in patients with HER2-positive gastric cancer in an oral presentation at 2025 ASCO GI – Presented Phase 1b/2 data …
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease
GlobeNewswire
·
March 6, 2025
FDA approves scPharmaceuticals’ supplemental New Drug Application to expand the FUROSCIX indication to include the treatment of edema in adult patients with chronic kidney disease, including nephrotic syndrome FUROSCIX is expected to be available for …
Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
GlobeNewswire
·
March 6, 2025
Topline Results for Phase 2b PROGRESS Study of Pilavapadin (LX9211) in Diabetic Peripheral Neuropathic Pain (DPNP); 10 mg dose to Advance into Phase 3 Development Leaner organization focused on Advancing Strong Pipeline Conference Call and Webcast at 5:00 …
Dr. Ameer E. Hassan and Summer Abu Jemeza Hassan Healthcare Grant Opens for Applications, Supporting the Next Generation of Healthcare Leaders
GlobeNewswire
·
March 6, 2025
HARLINGEN, Texas, March 06, 2025 (GLOBE NEWSWIRE) -- The Dr. Ameer E. Hassan and Summer Abu Jemeza Hassan Healthcare Grant is now accepting applications from undergraduate students across the United States pursuing careers in healthcare. This prestigious …
TCR Therapy Clinical Trial Pipeline Accelerates as 80+ Pharma Companies Rigorously Developing Drugs for the Market Entry | DelveInsight
GlobeNewswire
·
March 6, 2025
New York, USA, March 06, 2025 (GLOBE NEWSWIRE) -- TCR Therapy Clinical Trial Pipeline Accelerates as 80+ Pharma Companies Rigorously Developing Drugs for the Market Entry | DelveInsight T-cell receptor (TCR) therapy holds immense potential in …
Global Genome Editing Market to Grow Rapidly at a CAGR ~13% by 2032 | DelveInsight
GlobeNewswire
·
March 6, 2025
New York, USA, March 06, 2025 (GLOBE NEWSWIRE) -- Global Genome Editing Market to Grow Rapidly at a CAGR ~13% by 2032 | DelveInsight The growing occurrence of genetic disorders like sickle cell anemia, cystic fibrosis, and muscular dystrophy is fueling the …
Global AI in Cancer Diagnostics Market to Observe Stunning Growth at a CAGR ~11% by 2032 | DelveInsight
GlobeNewswire
·
March 6, 2025
New York, USA, March 06, 2025 (GLOBE NEWSWIRE) -- Global AI in Cancer Diagnostics Market to Observe Stunning Growth at a CAGR ~11% by 2032 | DelveInsight The increasing prevalence of cancer is driving the need for advanced diagnostic technologies, making …
Acetylcholine Receptor Antagonists Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
GlobeNewswire
·
March 6, 2025
New York, USA, March 06, 2025 (GLOBE NEWSWIRE) -- Acetylcholine Receptor Antagonists Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight Acetylcholine receptor antagonists are …
Global Zygomatic and Pterygoid Implant Market to Witness Upsurge in Growth at a CAGR of ~6% by 2032 | DelveInsight
GlobeNewswire
·
March 6, 2025
New York, USA, March 06, 2025 (GLOBE NEWSWIRE) -- Global Zygomatic and Pterygoid Implant Market to Witness Upsurge in Growth at a CAGR of ~6% by 2032 | DelveInsight The increasing occurrence of oral diseases and traumatic injuries worldwide largely fuels …
Global Single-use Bioreactors Market to Cross ~USD 10 Billion Mark by 2032 | DelveInsight
GlobeNewswire
·
March 6, 2025
New York, USA, March 06, 2025 (GLOBE NEWSWIRE) -- Global Single-use Bioreactors Market to Cross ~USD 10 Billion Mark by 2032 | DelveInsight The widespread adoption of single-use technologies, particularly in biopharmaceutical manufacturing, is fueled by …
Theriva™ Biologics participará en la Investor Summit Virtual del primer trimestre
GlobeNewswire
·
March 6, 2025
ROCKVILLE, Maryland, March 06, 2025 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), una empresa diversificada de fase clínica que desarrolla terapias diseñadas para tratar el cáncer y enfermedades relacionadas en áreas de gran carencia, ha …